INNOVATE • INTERACT • INVEST
Cancer Progress Conference 2022 Panels
Patients Front and Center
How to Catch and Treat Cancer Early
Stage of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much
The Latest Potential “Paradigm-Shifters”
ADC “The Next Generation”
Biotechs to Go It Alone - Launch Strategy for Success
How to Value Value: HEOR, HTA, ICER & Other Scary Acronyms for Oncology Developers!
What’s Hot/What’s Not for Startups in the Quasi-Post-Pandemic Oncology World?
Biotech versus Pharma Perspectives - Clinical Development Strategy
Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old-Fashioned Peptides - Is It the Target(s), Immunization Platform, Clin Dev Strategy, or All of the Above?
Does RNA Rule the World?
Growing Pains - Navigating the Precipitous Path Towards Commercialization
Tortoises and Hares - De-risking Strategies Towards Multiplexed Candidates
Selling the Cell - Cost-benefit Considerations for Complex Therapeutics
Building on Success - Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation
Tools of the Trade - Strategic Positioning of Emerging Cell Types, Target Discovery Engines, and Gene Engineering Tools
Battle of the Modalities: The Sequel to the Sequel - Revenge of the Nerds
Leading Companies and Institutions that attended Cancer Progress 2021